NineSigma has connected IAVI with some of the biomedical researchers, and helped it identify two scientists who will receive $875,000 to develop solutions for generating stable protein complexes for use in AIDS vaccines.
The grants were issued by the Innovation Fund, a program of IAVI.
NineSigma CEO Andy Zynga said open Innovation offers a new way to address and, we hope, solve problems impeding the development of effective HIV vaccines.
IAVI chief scientific officer Wayne Koff said they are confident that the researchers they helped identify have much to contribute to the development of an effective AIDS vaccine.